1. Treatment of Locally Advanced Pancreatic Cancer

2. Resectability of Pancreatic Adenocarcinoma at Diagnosis

3. Overview of Discussion

4. Phase 3 PRODIGE 24/CCTG PA.6 Trial Study Design

5. PRODIGE 24/CCTG PA.6 Trial Efficacy

6. PRODIGE 24/CCTG PA.6 Trial Disease-Free Survival

7. PRODIGE 24/CCTG PA.6 Trial Overall Survival

8. Phase 2 LAPACT Trial Study Design

9. LAPACT Trial Efficacy

10. Strengths and Limitations of the LAPACT Trial

11. Phase 3 LAP07 Trial Study Design

12. LAP07 Trial Efficacy in Gemcitabine-Only Arm

13. Phase 2 SCALOP Trial Study Design

14. SCALOP Trial Efficacy (Long-Term Follow-Up)

15. LAPACT Trial Best Response to Induction

16. LAPACT Trial Best Change From Baseline in Target Lesions

17. LAPACT Trial PFS and OS Kaplan-Meier Curves

18. LAPACT Trial Quality of Life During Induction

19. Summary of Clinical Trials Assessing Induction or Neoadjuvant Chemotherapy in LAPC

20. Phase 3 PREOPANC-1 Trial Study Design

21. PREOPANC-1 Trial Efficacy

22. PREOPANC-1 Trial Overall Survival in Intention to Treat Population

23. PREOPANC-1 Trial Overall Survival After R0/R1 Resection

24. PREOPANC-1 Trial Safety

25. LAPACT Trial Safety

26. PRODIGE Trial Key Takeaway

27. Emerging Role for Stereotactic Body Radiation Therapy in LAPC

28. New Standard of Care: Genetic Profiling in Pancreatic Cancer

29. ASCO® Guidelines for Potentially Curable Localized Pancreatic Adenocarcinoma

30. PRODIGE 24/CCTG PA.6 Trial Planned Dose Reduction of Irinotecan

31. PRODIGE 24/CCTG PA.6 Trial Adverse Events

32. LAPACT Trial–Toxicity Further Analysis

33. LAPACT Trial EORTC Quality-of-Life Scores (QLQ-C30)

34. Patient’s Overall Global Health With nab-Paclitaxel and Gemcitabine

35. Take-Home Points

36. Abbreviations

37. Abbreviations (cont)

38. Abbreviations (cont)